New HIV vaccine with a 97% antibody response rate shows promise in ‘landmark’ first-in-human trial
A novel vaccine approach for the prevention of HIV has shown promise in Phase I trials. IAVI and Scripps Research reported that the vaccine which is being developed to act as an immune primer, to trigger the activation of naïve B cells via a process called germline-targeting, as the first stage in a multi-step vaccine regimen to elicit…